Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 32, Number 11—November 2026

Research

Emergence of Novel Macrolide-Resistant Mycoplasma pneumoniae Sequence Type 3 Subclades in Children after COVID-19 Pandemic, Taiwan

Yu-Chia Hsieh, Chen-Ching Lin, Jia-Wen Wu, Yi-Hsuan Liu, Yi-Jiun Pan, Tzu-Ya Lo, Shian-Sen Shie, Huey-Ling You, Chong-Wei Huang, Yi-Chuan Huang, Tzu-Ching Huang, Yu-Xin She, Yin-Cheng Chen1, and Shiao-Wen Li1Comments to Author 
Author affiliation: Chang Gung Children’s Hospital, Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Taoyuan, Taiwan (Y.-C. Hsieh, J.-W. Wu, Y.-H. Liu, T.-Y. Lo); School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan (C.-C. Lin, Y.-C. Chen); School of Medicine, College of Medicine, People’s Republic of China Medical University, Taichung, Taiwan (Y.-J. Pan); Chang Gung Memorial Hospital, Taoyuan (S.-S. Shie); Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan (H.-L. You); Keelung Chang Gung Memorial Hospital, Keelung, Taiwan (C.-W. Huang, Y.-C. Huang); School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei (T.-C. Huang); College of Science Department of Life Sciences, National University of Kaohsiung, Kaohsiung (Y.-X. She, S.-W. Li)

Main Article

Table 3

Macrolide-resistant Mycoplasma pneumoniae strains and antimicrobial susceptibility to 10 agents in study of emergence of novel macrolide-resistant M. pneumoniae sequence type 3 subclades in children after COVID-19 pandemic*

Antimicrobial agent Macrolide-resistant M. pneumoniae with A2063G mutation, n = 109
MIC50 MIC90 MIC range
Macrolide
Erythromycin 64 128 16–256
Azithromycin 16 32 1–128
Clarithromycin
 32
 128
 2–128
Quinolones
Levofloxacin 0.25 0.5 0.03–0.5
Moxifloxacin 0.03 0.06 <0.03–0.06
Ciprofloxacin 0.5 1 0.06–1
Tosufloxacin
 0.06
 0.125
 0.03–0.25
Tetracyclines
Doxycycline <0.03 0.03 <0.03–0.125
Minocycline 0.03 0.06 <0.03–0.125
Omadacycline 0.06 0.125 0.03–0.125

*MIC50, MIC at which 50% of antimicrobial is inhibited; MIC90, MIC at which 90% of antimicrobial is inhibited.

Main Article

1These senior authors contributed equally to this article.

Page created: September 05, 2026
Page updated: October 14, 2026
Page reviewed: October 14, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external